Targeting DMARD therapy

  • Maria E. Suarez-Almazor
Part of the Progress in Inflammation Research book series (PIR)


Medical advances in the past few years have opened an exciting era in the treatment of rheumatoid arthritis (RA). For the first time, physicians and their patients are faced with a variety of therapeutic choices in the management of RA and must make decisions about specific disease-modifying antirheumatic drugs (DMARDs), including potential combinations of different agents. A careful balance of short-term and long-term benefits and risks must be considered. In addition, financial and societal issues play a role in these already complex therapeutic decisions with increasing frequency. The cost of healthcare has skyrocketed in the past decades. Policymakers, physicians and their patients are faced everyday with decisional conflicts coupled with constraints in health budgets around the world, that must balance not only health outcomes, but also economic costs to patients, providers and society at large. These considerations are particularly salient when assessing the therapeutic benefits of the newly developed biologic agents which are substantially more costly than traditional DMARDS, but which could be cost-effective if they reduce long-term damage and disability.


Early Rheumatoid Arthritis Shared Epitope Toid Arthritis DMARD Therapy Radiographic Damage 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Aday LA, Begley CE, Lairson DR, Slater CH (1998) Evaluating the Healthcare System: Effectiveness, Efficiency, and Equity. Second ed. Health Administration Press, ChicagoGoogle Scholar
  2. 2.
    Haynes RB, Devereaux PJ, Guyatt GH (2002) Physicians’ and patients’ choices in evidence based practice. BMJ 324 (7350): 1350PubMedGoogle Scholar
  3. 3.
    Guyatt GH, Sinclair J, Cook DJ, Glasziou P (1999) Users’ guides to the medical literature: XVI. How to use a treatment recommendation. Evidence-Based Medicine Working Group and the Cochrane Applicability Methods Working Group. JAMA 281 (19): 1836–1843PubMedGoogle Scholar
  4. 4.
    Sackett DL, Straus S, Richardson SW, Rosenberg W, Hanes BR (2000) Evidence-based medicine: How to practice and teach EBM. 2nd ed. Churchill Livingstone, EdinburghGoogle Scholar
  5. 5.
    Guyatt GH, Sackett DL, Sinclair JC, Hay ward R, Cook DJ, Cook RJ (1995) Users’ guides to the medical literature. IX. A method for grading health care recommendations. Evidence-Based Medicine Working Group. JAMA 274 (22): 1800–1804PubMedGoogle Scholar
  6. 6.
    Chalmers I, Altman DG (1995) Systematic reviews. BMJ Publishing Group, LondonGoogle Scholar
  7. 7.
    Boers M, Tugwell P, Felson DT, van Riel PL, Kirwan JR, Edmonds JP et al (1994) World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol (Suppl) 41: 86–89Google Scholar
  8. 8.
    Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B et al (1993) The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 36 (6): 729–740PubMedGoogle Scholar
  9. 9.
    Felson DT, Anderson JJ, Boers M, Bombardier C, Fürst D, Goldsmith C et al (1995) American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38 (6): 727–735PubMedGoogle Scholar
  10. 10.
    van Gestel AM, Anderson JJ, van Riel PL, Boers M, Haagsma CJ, Rich B et al (1999) ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology. J Rheumatol 26 (3): 705–711PubMedGoogle Scholar
  11. 11.
    Cook RJ, Sackett DL (1995) The number needed to treat: a clinically useful measure of treatment effect. BMJ 310 (6977): 452–454PubMedGoogle Scholar
  12. 12.
    Laupacis A, Sackett DL, Roberts RS (1988) An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 318 (26): 1728–1733PubMedCrossRefGoogle Scholar
  13. 13.
    Green M, Marzo-Ortega H, McGonagle D, Wakefield R, Proudman S, Conaghan P et al (1999) Persistence of mild, early inflammatory arthritis: the importance of disease duration, rheumatoid factor, and the shared epitope. Arthritis Rheum 42 (10): 2184–2188PubMedGoogle Scholar
  14. 14.
    Guidelines for the management of rheumatoid arthritis (2002) 2002 Update. Arthritis Rheum 46 (2): 328–346Google Scholar
  15. 15.
    Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH, Smolen JS (2002) Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 61 (4): 290–297PubMedGoogle Scholar
  16. 16.
    Quinn MA, Conaghan PG, Emery P (2001) The therapeutic approach of early intervention for rheumatoid arthritis: what is the evidence? Rheumatology (Oxford) 40 (11): 1211–1220Google Scholar
  17. 17.
    Munro R, Hampson R, McEntegart A, Thomson EA, Madhok R, Capell H (1998) Improved functional outcome in patients with early rheumatoid arthritis treated with intramuscular gold: results of a five year prospective study. Ann Rheum Dis 57 (2): 88–93PubMedGoogle Scholar
  18. 18.
    Tsakonas E, Fitzgerald AA, Fitzcharles MA, Cividino A, Thorne JC, M’Seffar A et al (2000) Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year follow up on the hydroxychloroquine in early rheumatoid arthritis (HERA) study. J Rheumatol 27 (3): 623–629PubMedGoogle Scholar
  19. 19.
    O’Dell JR, Haire CE, Palmer W, Drymalski W, Wees S, Blakely K et al (1997) Treatment of early rheumatoid arthritis with minocycline or placebo: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 40 (5): 842–848PubMedGoogle Scholar
  20. 20.
    Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC et al (1997) Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350 (9074): 309–318PubMedGoogle Scholar
  21. 21.
    Landewe RB, Boers M, Verhoeven AC, Westhovens R, van de Laar MA, Markusse HM et al (2002) COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 46 (2): 347–356PubMedGoogle Scholar
  22. 22.
    Möttönen T, Hannonen P, Korpela M, Nissila M, Kautiainen H, Honen J et al (2002) Delay to institution of therapy and induction of remission using single-drug or combi-nation-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 46 (4): 894–898PubMedGoogle Scholar
  23. 23.
    Felson DT, Anderson JJ, Meenan RF (1990) The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum 33 (10): 1449–1461PubMedGoogle Scholar
  24. 24.
    Felson DT, Anderson JJ, Meenan RF (1992) Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. Arthritis Rheum 35 (10): 1117–1125PubMedGoogle Scholar
  25. 25.
    Suarez-Almazor ME, Osiri M, Emery P, Ottawa Methods Group (2004) Rheumatoid arthritis. In: Tugwell P, Shea B, Boers M, Brooks P, Simon LS, Strand V et al (eds): Evidence-based rheumatology. BMJ Publishing Group, London, 243–314Google Scholar
  26. 26.
    Gotzsche PC, Podenphant J, Olesen M, Halberg P (1992) Meta-analysis of second-line antirheumatic drugs: sample size bias and uncertain benefit. J Clin Epidemiol 45 (6): 587–594PubMedGoogle Scholar
  27. 27.
    Haagsma CJ, van Riel PL, de Jong AJ, van de Putte LB (1997) Combination of sul-phasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol 36 10): 1082–1088PubMedGoogle Scholar
  28. 28.
    Dougados M, Combe B, Cantagrel A, Goupille P, Olive P, Schattenkirchner M et al (1999) Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis 58 (4): 220–225PubMedGoogle Scholar
  29. 29.
    Klareskog L, van der HD, de Jager JP, Gough A, Kalden J, Malaise M et al (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363 (9410): 675–681PubMedGoogle Scholar
  30. 30.
    Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC et al (2000) A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343 (22): 1586–1593PubMedGoogle Scholar
  31. 31.
    Osiri M, Suarez-Almazor ME, Wells GA, Robinson V, Tugwell P (2003) Number needed to treat (NNT): implication in rheumatology clinical practice. Ann Rheum Dis 62 (4): 316–321PubMedGoogle Scholar
  32. 32.
    Suarez-Almazor ME, Soskolne CL, Saunders LD, Russell AS (1995) Use of second line drugs for the treatment of rheumatoid arthritis in Edmonton, Alberta. Patterns of prescription and long term effectiveness. J Rheumatol 22 (5): 836–843PubMedGoogle Scholar
  33. 33.
    Wolfe F, Hawley DJ, Cathey MA (1990) Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 17 (8): 994–1002PubMedGoogle Scholar
  34. 34.
    Maetzel A, Wong A, Strand V, Tugwell P, Wells G, Bombardier C (2000) Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving diseasemodifying anti-rheumatic drugs. Rheumatology (Oxford) 39 (9): 975–981Google Scholar
  35. 35.
    Fürst DE (1995) Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis. Br J Rheumatol 34 (2): 20–25PubMedGoogle Scholar
  36. 36.
    Green M, Marzo-Ortega H, McGonagle D, Wakefield R, Proudman S, Conaghan P et al (1999) Persistence of mild, early inflammatory arthritis: the importance of disease duration, rheumatoid factor, and the shared epitope. Arthritis Rheum 42 (10): 2184–2188PubMedGoogle Scholar
  37. 37.
    Gough A, Faint J, Salmon M, Hassell A, Wordsworth P, Pilling D et al (1994) Genetic typing of patients with inflammatory arthritis at presentation can be used to predict outcome. Arthritis Rheum 37 (8): 1166–1170PubMedGoogle Scholar
  38. 38.
    Jansen AL, van der Horst-Bruinsma I, van Schaardenburg D, van de Stadt RJ, de Koning MH, Dijkmans BA (2002) Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol 29 (10): 2074–2076PubMedGoogle Scholar
  39. 39.
    Masi AT (1983) Articular patterns in the early course of rheumatoid arthritis. Am J Med 75 (6A): 16–26PubMedGoogle Scholar
  40. 40.
    Tunn EJ, Bacon PA (1993) Differentiating persistent from self-limiting symmetrical synovitis in an early arthritis clinic. Br J Rheumatol 32 (2): 97–103PubMedGoogle Scholar
  41. 41.
    Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM (2002) How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 46 (2): 357–365PubMedGoogle Scholar
  42. 42.
    Wolfe F, Ross K, Hawley DJ, Roberts FK, Cathey MA (1993) The prognosis of rheumatoid arthritis and undifferentiated polyarthritis syndrome in the clinic: a study of 1141 patients. J Rheumatol 20 (12): 2005–2009PubMedGoogle Scholar
  43. 43.
    Mottonen T, Paimela L, Leirisalo-Repo M, Kautiainen H, Honen J, Hannonen P (1998) Only high disease activity and positive rheumatoid factor indicate poor prognosis in patients with early rheumatoid arthritis treated with “sawtooth” strategy. Ann Rheum Dis 57 (9): 533–539PubMedGoogle Scholar
  44. 44.
    Brennan P, Harrison B, Barrett E, Chakravarty K, Scott D, Silman A et al (1996) A simple algorithm to predict the development of radiological erosions in patients with early rheumatoid arthritis: prospective cohort study. BMJ 313 (7055): 471–476PubMedGoogle Scholar
  45. 45.
    Bukhari M, Lunt M, Harrison BJ, Scott DG, Symmons DP, Silman AJ (2002) Rheumatoid factor is the major predictor of increasing seventy of radiographic erosions in rheumatoid arthritis: results from the Norfolk Arthritis Register Study, a large inception cohort. Arthritis Rheum 46 (4): 906–912PubMedGoogle Scholar
  46. 46.
    Combe B, Dougados M, Goupille P, Cantagrel A, Eliaou JF, Sibilia J et al (2001) Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. Arthritis Rheum 44 (8): 1736–1743PubMedGoogle Scholar
  47. 47.
    Drossaers-Bakker KW, Zwinderman AH, Vlieland TP, van Zeben D, Vos K, Breedveld FC et al (2002) Long-term outcome in rheumatoid arthritis: a simple algorithm of baseline parameters can predict radiographic damage, disability, and disease course at 12-year follow up. Arthritis Rheum 47 (4): 383–390PubMedGoogle Scholar
  48. 48.
    Feigenbaum SL, Masi AT, Kaplan SB (1979) Prognosis in rheumatoid arthritis. A longitudinal study of newly diagnosed younger adult patients. Am J Med 66 (3): 377–384PubMedGoogle Scholar
  49. 49.
    Fex E, Jonsson K, Johnson U, Eberhardt K (1996) Development of radiographic damage during the first 5-6 yr of rheumatoid arthritis. A prospective follow-up study of a Swedish cohort. Br J Rheumatol 35 (11): 1106–1115PubMedGoogle Scholar
  50. 50.
    Harrison B, Thomson W, Symmons D, Ollier B, Wiles N, Payton T et al (1999) The influence of HLA-DRB1 alleles and rheumatoid factor on disease outcome in an inception cohort of patients with early inflammatory arthritis. Arthritis Rheum 42 (10): 2174–2183PubMedGoogle Scholar
  51. 51.
    Jansen LM, van Schaardenburg D, van der Horst-Bruinsma E, Bezemer PD, Dijkmans BA (2000) Predictors of functional status in patients with early rheumatoid arthritis. Ann Rheum Dis 59 (3): 223–226PubMedGoogle Scholar
  52. 52.
    Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van’t Hof M et al (2000) The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 43 (8): 1831–1835PubMedGoogle Scholar
  53. 53.
    van der HA, Remme CA, Hofman DM, Jacobs JW, Bijlsma JW (1995) Prediction of progression of radiologic damage in newly diagnosed rheumatoid arthritis. Arthritis Rheum 38 (10): 1466–1474Google Scholar
  54. 54.
    van der Heijde DM, van Riel PL, van Leeuwen MA, van’t-Hof MA, van Rijswijk MH, van de Putte LB (1992) Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients. Br J Rheumatol 31 (8): 519–525PubMedGoogle Scholar
  55. 55.
    van Leeuwen MA, Westra J, van Riel PL, Limburg PC, van Rijswijk MH (1995) IgM, IgA, and IgG rheumatoid factors in early rheumatoid arthritis predictive of radiological progression? Scand J Rheumatol 24 (3): 146–153PubMedGoogle Scholar
  56. 56.
    Corbett M, Dalton S, Young A, Silman A, Shipley M (1993) Factors predicting death, survival and functional outcome in a prospective study of early rheumatoid disease over fifteen years. Br J Rheumatol 32 (8): 717–723PubMedGoogle Scholar
  57. 57.
    Suarez-Almazor ME, Soskolne CL, Saunders LD, Russell AS (1994) Outcome in rheumatoid arthritis. A 1985 inception cohort study. J Rheumatol 21 (8): 1438–1446PubMedGoogle Scholar
  58. 58.
    Suarez-Almazor ME, Tao S, Moustarah F, Russell AS, Maksymowych W (1995) HLA-DR1, DR4, and DRB1 disease related subtypes in rheumatoid arthritis. Association with susceptibility but not severity in a city wide community based study. J Rheumatol 22 (11): 2027–2033PubMedGoogle Scholar
  59. 59.
    Gorman JD, Lum RF, Chen JJ, Suarez-Almazor ME, Thomson G, Criswell LA (2004) Impact of shared epitope genotype and ethnicity on erosive disease: a meta-analysis of 3,240 rheumatoid arthritis patients. Arthritis Rheum 50 (2): 400–412PubMedGoogle Scholar
  60. 60.
    Tanaka E, Taniguchi A, Urano W, Yamanaka H, Kamatani N (2004) Pharmacogenetics of disease-modifying anti-rheumatic drugs. Best Bract Res Clin Rheumatol 18 (2): 233–247Google Scholar
  61. 61.
    Reveille JD, Alarcon GS, Fowler SE, Pillemer SR, Neuner R, Clegg DO et al (1996) HLA-DRB1 genes and disease severity in rheumatoid arthritis. The MIRA Trial Group. Minocycline in Rheumatoid Arthritis. Arthritis Rheum 39 (11): 1802–1807PubMedGoogle Scholar
  62. 62.
    O’Dell JR, Nepom BS, Haire C, Gersuk VH, Gaur L, Moore GF et al (1998) HLA-DRB1 typing in rheumatoid arthritis: predicting response to specific treatments. Ann Rheum Dis 57 (4): 209–213PubMedGoogle Scholar
  63. 63.
    Lard LR, Visser H, Speyer I, vander Horst-Bruinsma E, Zwinderman AH, Breedveld FC et al (2001) Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 111 (6): 446–451PubMedGoogle Scholar
  64. 64.
    Lard LR, Boers M, Verhoeven A, Vos K, Visser H, Hazes JM et al (2002) Early and aggressive treatment of rheumatoid arthritis patients affects the association of HLA class II antigens with progression of joint damage. Arthritis Rheum 46 (4): 899–905PubMedGoogle Scholar
  65. 65.
    Fabris M, Tolusso B, Di Poi E, Assaloni R, Sinigaglia L, Ferraccioli G (2002) Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis. J Rheumatol 29 (9): 1847–1850PubMedGoogle Scholar
  66. 66.
    Padyukov L, Lampa J, Heimburger M, Ernestam S, Cederholm T, Lundkvist I et al (2003) Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis 62 (6): 526–529PubMedGoogle Scholar
  67. 67.
    Martinez A, Salido M, Bonilla G, Pascual-Salcedo D, Fernandez-Arquero M, de Miguel S et al (2004) Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients. Arthritis Rheum 50 (4): 1077–1082PubMedGoogle Scholar
  68. 68.
    Kumagai K, Hiyama K, Oyama T, Maeda H, Kohno N (2003) Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. Int J Mol Med 11 (5): 593–600PubMedGoogle Scholar
  69. 69.
    Urano W, Taniguchi A, Yamanaka H, Tanaka E, Nakajima H, Matsuda Y et al (2002) Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 12 (3): 183–190PubMedGoogle Scholar
  70. 70.
    Fraenkel L, Bogardus S, Concato J, Felson D (2001) Preference for disclosure of information among patients with rheumatoid arthritis. Arthritis Rheum 45 (2): 136–139PubMedGoogle Scholar
  71. 71.
    Briss P, Rimer B, Reilley B, Coates RC, Lee NC, Mullen P et al (2004) Promoting informed decisions about cancer screening in communities and healthcare systems. Am J Prev Med 26 (1): 67–80PubMedGoogle Scholar
  72. 72.
    Tversky A, Kahneman D (1981) The framing of decisions and the psychology of choice. Science 211 (4481): 453–458PubMedGoogle Scholar
  73. 73.
    Fraenkel L, Bogardus S, Concato J, Felson D (2002) Unwillingness of rheumatoid arthritis patients to risk adverse effects. Rheumatology (Oxford) 41 (3): 253–261Google Scholar
  74. 74.
    Fraenkel L, Bogardus S, Concato J, Felson D (2003) Risk communication in rheumatoid arthritis. J Rheumatol 30 (3): 443–448PubMedGoogle Scholar
  75. 75.
    Fraenkel L, Bogardus ST, Concato J, Felson DT, Wittink DR (2004) Patient preferences for treatment of rheumatoid arthritis. Ann Rheum Dis; in pressGoogle Scholar
  76. 76.
    O’Connor AM, Rostom A, Fiset V, Tetroe J, Entwistle V, Llewellyn-Thomas H et al (1999) Decision aids for patients facing health treatment or screening decisions: systematic review. BMJ 319 (7212): 731–734PubMedGoogle Scholar
  77. 77.
    O’Connor AM, Legare F, Stacey D (2003) Risk communication in practice: the contribution of decision aids. BMJ 327 (7417): 736–740PubMedGoogle Scholar
  78. 78.
    Gabriel SE, Crowson CS, Luthra HS, Wagner JL, O’Fallon WM (1999) Modeling the lifetime costs of rheumatoid arthritis. J Rheumatol 26 au](6): 1269–1274PubMedGoogle Scholar
  79. 79.
    Wong JB, Ramey DR, Singh G (2001) Long-term morbidity, mortality, and economics of rheumatoid arthritis. Arthritis Rheum 44 (12): 2746–2749PubMedGoogle Scholar
  80. 80.
    Yelin E, Wanke LA (1999) An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum 42 (6): 1209–1218PubMedGoogle Scholar
  81. 81.
    Cooper NJ (2000) Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 39 (1): 28–33Google Scholar
  82. 82.
    Clarke AE, Levinton C, Joseph L, Penrod J, Zowall H, Sibley JT et al (1999) Predicting the short term direct medical costs incurred by patients with rheumatoid arthritis. J Rheumatol 26 (5): 1068–1075PubMedGoogle Scholar
  83. 83.
    Ruof J, Hulsemann JL, Mittendorf T, Handelmann S, der Schulenburg JM, Zeidler H et al (2003) Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer’s data sources. Ann Rheum Dis 62 (6): 544–549PubMedGoogle Scholar
  84. 84.
    Cooper NJ, Mugford M, Scott DG, Barrett EM, Symmons DP (2000) Secondary health service care and second line drug costs of early inflammatory polyarthritis in Norfolk, UK. J Rheumatol 27 (9): 2115–2122PubMedGoogle Scholar
  85. 85.
    Lübeck DP (2001) A review of the direct costs of rheumatoid arthritis: managed care versus fee-for-service settings. Pharmacoeconomics 19 (8): 811–818PubMedGoogle Scholar
  86. 86.
    Blomqvist P, Feltelius N, Ekbom A, Klareskog L (2000) Rheumatoid arthritis in Sweden. Drug prescriptions, costs, and adverse drug reactions. J Rheumatol 27 (5): 1171–1177PubMedGoogle Scholar
  87. 87.
    Callahan LF (1998) The burden of rheumatoid arthritis: facts and figures. J Rheumatol (Suppl) 53: 8–12Google Scholar
  88. 88.
    Lajas C, Abasolo L, Bellajdel B, Hernandez-Garcia C, Carmona L, Vargas E et al (2003) Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Rheum 49 (1): 64–70PubMedGoogle Scholar
  89. 89.
    Pugner KM, Scott DI, Holmes JW, Hieke K (2000) The costs of rheumatoid arthritis: an international long-term view. Semin Arthritis Rheum 29 (5): 305–320PubMedGoogle Scholar
  90. 90.
    Kobelt G, Jonsson L, Lindgren P, Young A, Eberhardt K (2002) Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis. Arthritis Rheum 46 (9): 2310–2319PubMedGoogle Scholar
  91. 91.
    Newhall-Perry K, Law NJ, Ramos B, Sterz M, Wong WK, Bulpitt KJ et al (2000) Direct and indirect costs associated with the onset of seropositive rheumatoid arthritis. Western Consortium of Practicing Rheumatologists. J Rheumatol 27 (5): 1156–1163PubMedGoogle Scholar
  92. 92.
    Sokka T (2003) Work disability in early rheumatoid arthritis. Clin Exp Rheumatol 21 (5 Suppl 31): S71–S74PubMedGoogle Scholar
  93. 93.
    Merkesdal S, Ruof J, Schoffski O, Bernitt K, Zeidler H, Mau W (2001) Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease. Arthritis Rheum 44 (3): 528–534PubMedGoogle Scholar
  94. 94.
    van Jaarsveld CH, Jacobs JW, Schrijvers AJ, Heurkens AH, Haanen HC, Bijlsma JW (1998) Direct cost of rheumatoid arthritis during the first six years: a cost-of-illness study. Br J Rheumatol 37 (8): 837–847PubMedGoogle Scholar
  95. 95.
    Michaud K, Messer J, Choi HK, Wolfe F (2003) Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum 48 (10): 2750–2762Google Scholar
  96. 96.
    Gabriel SE, Coyle D, Moreland LW (2001) A clinical and economic review of diseasemodifying antirheumatic drugs. Pharmacoeconomics 19 (7): 715–728PubMedGoogle Scholar
  97. 97.
    Yelin E, Trupin L, Katz P, Lübeck D, Rush S, Wanke L (2003) Association between etanercept use and employment outcomes among patients with rheumatoid arthritis. Arthritis Rheum 48 (11): 3046–3054PubMedGoogle Scholar
  98. 98.
    Dayhoff JE, DeLeo JM (2001) Artificial neural networks: opening the black box. Cancer 91 (8 Suppl): 1615–1635PubMedGoogle Scholar
  99. 99.
    Almeida JS (2002) Predictive non-linear modeling of complex data by artificial neural networks. Curr Opin Biotechnol 13 (1): 72–76PubMedGoogle Scholar
  100. 100.
    Sargent DJ (2001) Comparison of artificial neural networks with other statistical approaches: results from medical data sets. Cancer 91 (8 Suppl): 1636–1642PubMedGoogle Scholar
  101. 101.
    Di Blasio CJ, Rhee AC, Cho D, Scardino PT, Kattan MW (2003) Predicting clinical end points: treatment nomograms in prostate cancer. Semin Oncol 30 (5): 567–586PubMedGoogle Scholar
  102. 102.
    Esdaile JM, Suissa S, Shiroky JB, Lamping D, Tsakonas E, Anderson D et al (1995) A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA study. Am J Med 98: 156–168Google Scholar
  103. 103.
    Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A et al (1999) Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 353 (9149): 259–266PubMedGoogle Scholar
  104. 104.
    Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G et al (1999) Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 159 (21): 2542–2550PubMedGoogle Scholar
  105. 105.
    Williams HJ, Willkens RF, Samuelson CO Jr, Alarcon GS, Guttadauria M, Yarboro C et al (1985) Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 28 (7): 721–730PubMedGoogle Scholar
  106. 106.
    Osiri M, Shea B, Robinson V, Suarez-Almazor M, Strand V, Tugwell P et al (2003) Leflunomide for treating rheumatoid arthritis. Cochrane Database Syst Rev (1): CD002047Google Scholar
  107. 107.
    Ferraccioli GF, Gremese E, Tomietto P, Favret G, Damato R, Di Poi E (2002) Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years. Rheumatology (Oxford) 41 (8): 892–898Google Scholar
  108. 108.
    Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH et al (2002) Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 46 (6): 1443–1450PubMedGoogle Scholar
  109. 109.
    Maini R, St Clair EW, Breedveld F, Fürst D, Kalden J, Weisman M et al (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354 (9194): 1932–1939PubMedGoogle Scholar
  110. 110.
    Lipsky PE, van der Heijde DM, St Clair EW, Fürst DE, Breedveld FC, Kalden JR et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343 (22): 1594–1602PubMedGoogle Scholar
  111. 111.
    Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI et al (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340 (4): 253–259PubMedGoogle Scholar
  112. 112.
    Moreland LW, Schiff MH, Baumgartner SW, Tindali EA, Fleischmann RM, Bulpitt KJ et al (1999) Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130 (6): 478–486PubMedGoogle Scholar
  113. 113.
    Weinblatt ME, Keystone EC, Fürst DE, Moreland LW, Weisman MH, Birbara CA et al (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48 (1): 35–45PubMedGoogle Scholar
  114. 114.
    Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW et al (2002) Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46 (3): 614–624PubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag Basel/Switzerland 2005

Authors and Affiliations

  • Maria E. Suarez-Almazor
    • 1
  1. 1.Baylor College of Medicine, Houston Center for Quality of Care and Utilization StudiesMichael E. DeBakey VA Medical CenterHoustonUSA

Personalised recommendations